|
1) Schwartz IF, Iaina A. Uraemic pruritus. Nephrol Dialysis Transplant. 1999; 14: 834
|
|
|
|
|
2) Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet. 2003; 361: 690
|
|
|
|
|
3) Mettang T, Pauli-Magnus U, Alscher DM. Uraemic pruritus-new perspectives and insights from recent trials. Nephrol Dial Transplant. 2002; 17: 1558
|
|
|
|
|
|
4) Ikoma A, Steinhoff M, Schmelz M, et al. The neurobiology of itch. Nature Rev Neurosci. 2006; 7: 535
|
|
|
|
|
|
5) Pisoni R, Wikström B, Akizawa T, et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2006; 21: 3495
|
|
|
|
|
|
6) 大森健太郎, 成田一衛, 下条文武, 他. 透析皮膚掻痒症の実態― 新潟県内41施設2474名の調査報告―. 日本透析会誌. 2001; 34: 1469
|
|
|
|
|
|
7) Narita I, Omori K, Gejyo F, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int. 2006; 69: 1626
|
|
|
|
|
|
8) Kumagai H, Ebata T, Suzuki H, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomised, double-blind, placebo-controlled study. Nephrology Dialysis Transplantation. 2010; 25: 1251
|
|
|
|
|
|
9) Kumagai H, Utsumi J, Saruta T, et al. Prospects for a novel κ-opioid receptor agonist, TRK-820, in uremic pruritus. In: Yosipovitch G, editor. Itch. Basic Mechanisms and Therapy. New York: Marcel Dekker; 2004. p.279-86
|
|
|
|
|
|
10) 熊谷裕生, 丸山資郎, 高森建二, 他. 透析患者のかゆみに対するκ-アゴニストTRK-820. 透析治療における新しい薬物. 臨床透析. 2006; 22: 763
|
|
|
|
|
11) Peer G, Kivity S, Aqami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet. 1996; 348: 1552
|
|
|
|
|
|
12) Pauli-Magus C, Mikus T, Mettang T, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, placebo-conrolled crossover-study. J Am Soc Nephrol. 2000; 11: 514
|
|
|
|
|
|
13) Pan ZZ. μ-Opposing actions of the κ-opioid receptor. Trend in Pharmacol Sci. 1998; 19: 94
|
|
|
|
|
|
14) Margolis EB, Hjelmstad GO, Bonci A, et al. κ-Opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosci. 2003; 23: 9981
|
|
|
|
|
|
15) 鈴木知比古, 内海 潤, 熊谷裕生, 他. RT-PCR によるヒト末梢血リンパ球のオピオイド受容体およびノシセプチン受容体の発現解析. 臨床薬理. 2000; 31: 455
|
|
|
|
|
|
16) Togashi Y, Umeuchi K, Nagase H, et al. Antipruric activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol. 2002; 435: 259
|
|
|
|
|
|
17) Seki T, Awamura S, Kimura C, et al. Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor. Eur J Pharmacol. 1999; 376: 159
|
|
|
|
|
|
18) Nagase H, Hayakawa J, Kawamura K, et al. Discovery of a structurally novel opioid kappa-agonist derived from 4, 5-epoxymorphinan. Chem Pharm Bull. 1998; 46: 366
|
|
|
|
|
|
19) Wakasa Y, Fujiwara A, Nagase H, et al. Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys. Life Sci. 2004; 75: 2947
|
|
|
|
|
|
20) Umeuchi H, Togashi Y, Nagase H, et al. Involvement of central μ-opioid system in the scratching behavior in mice, and the suppression of it by the activation of κ-opioid system. Eur J Pharmacol. 2003; 477: 29
|
|
|
|
|
|
21) Kamei J, Nagase H. Norbinaltorphimine, a selective κ-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol. 2001; 418: 141
|
|
|
|
|
|
22) Bigliardi PL, Bigliardi-Qi M, Buechner S, et al. Expression of μ-opiate receptor in human epidermis and keratinocytes. J Invest Dermatol. 1998; 111: 297
|
|
|
|
|
|
23) Bigliardi PL, Strammer H, Jost G, et al. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol. 2007; 56: 979
|
|
|
|
|
|
24) Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol. 2007; 127: 2228
|
|
|
|
|
|
25) 熊谷裕生, 江畑俊哉, 鈴木洋通, 他. 血液透析患者のかゆみに対する, カッパ受容体作動薬ナルフラフィンの有効性. 日本透析医会雑誌. 2009; 24: 387
|
|
|
|
|